Status:
COMPLETED
Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study
Lead Sponsor:
Mayo Clinic
Conditions:
Myocardial Inflammation
Rheumatoid Arthritis
Eligibility:
All Genders
40+ years
Brief Summary
Rheumatoid arthritis (RA) patients have a higher prevalence of subclinical atherosclerosis than the general population. In addition, RA patients experience higher rates of heart failure with preserved...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Diagnosis of Rheumatoid Arthritis according to 2010 American College of Rheumatology (ACR) criteria (14)
- RA disease duration ≤ 10 years since diagnosis
- Able to provide informed consent
- Exclusion Criteria
- Known clinical atherosclerotic disease (myocardial infarction, severe obstruction CAD (≥ 1 untreated stenosis (≥ 70% in a major vessel) known by either invasive or noninvasive testing), prior coronary artery intervention, prior coronary artery bypass surgery, cerebrovascular event, peripheral vascular disease).
- Prednisone \>10mg per day (or equivalent corticosteroid dose per day within last week)
- Irregular heart rhythm (arrhythmia or cardiac conduction abnormality (e.g. atrial fibrillation or flutter, frequent extrasystole, LBBB)
- Relevant valvular heart disease (\> moderate regurgitation or stenosis of any heart valve)
- Clinical occurrence of heart failure with or without preserved ejection fraction
- Impaired imaging quality or other contraindications for myocardial strain imaging
- Relevant lung disease (including severe COPD with oxygen dependence, fibrosis, symptomatic pleural effusion, oxygen dependence)
- Sarcoidosis
- Diabetes mellitus treated with insulin
- estimated glomerular filtration rate (eGFR) \< 40ml/min
- Known cancer
- History of any-type of cardiomyopathy (e.g. cardiac amyloidosis, hypertrophic cardiomyopathy,...)
- Ejection fraction (EF) less than 45%
- Life expectancy \< 1 year
- BMI \>40kg/m2
- Severe claustrophobia
- Any known allergic reactions to intravenous contrast
- Inability to receive beta blocker therapy or IV nitrates
- Pregnant/ Breastfeeding women
- Vulnerable persons due to Helsinki Declaration
- Unable to provide informed consent
Exclusion
Key Trial Info
Start Date :
June 22 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 26 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT03776682
Start Date
June 22 2018
End Date
May 26 2023
Last Update
July 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905